NCT01303341 2026-03-18
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
23 trialsNCT00602576 2022-06-14
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT00387751 2017-11-22
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00418496 2017-02-20
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01078961 2016-06-08
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Massachusetts General Hospital
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00673361 2016-01-13
Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma
Duke University
Phase 2 Terminated
NCT00110019 2015-10-19
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00110994 2015-06-08
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 2 Completed
NCT01851408 2015-04-15
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00565968 2015-03-06
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
Duke University
Phase 1 Completed
NCT00111007 2014-10-31
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 3 Completed
NCT00492297 2014-10-31
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
Bayer
Phase 2 Completed
NCT00281957 2014-05-20
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00349206 2014-04-10
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00827177 2014-01-24
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00492505 2014-01-10
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00538005 2014-01-10
Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00119249 2013-01-15
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00483301 2012-05-03
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
Mt. Sinai Medical Center, Miami
Phase 2 Completed
NCT00623402 2011-01-12
SoraPeg
University Hospital Schleswig-Holstein
Phase 2 Completed
NCT00811759 2010-10-07
Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00794235 2010-01-08
Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine
University of Zurich
Phase 2 Completed